Liver Cancer in 2021: Global Burden of Disease Study.

alcohol hepatitis B hepatitis C hepatocellular carcinoma hepatoma metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease steatotic liver disease

Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
29 Oct 2024
Historique:
received: 22 07 2024
revised: 12 10 2024
accepted: 20 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 31 10 2024
Statut: aheadofprint

Résumé

The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021. Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease. In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer. While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
The epidemiology of adult primary liver cancer continues to evolve, related to the increasing prevalence of metabolic disease, rising alcohol consumption, advancements in vaccination for hepatitis B (HBV), and antiviral therapy for hepatitis C (HCV). Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.
METHODS METHODS
Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease.
RESULTS RESULTS
In 2021, there were an estimated 529202 incident cases and 483875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Global age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer.
CONCLUSIONS CONCLUSIONS
While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and MASLD-related liver cancer continues to surge.

Identifiants

DOI: 10.1016/j.jhep.2024.10.031 PMID: 39481652
pubmed: 39481652
pii: S0168-8278(24)02652-7
doi: 10.1016/j.jhep.2024.10.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

En Ying Tan (EY)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

Pojsakorn Danpanichkul (P)

Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, Texas, USA.

Jie Ning Yong (JN)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Zhenning Yu (Z)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Darren Jun Hao Tan (DJH)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Wen Hui Lim (WH)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Benjamin Koh (B)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Ryan Yan Zhe Lim (RYZ)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Ethan Kai Jun Tham (EKJ)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Kartik Mitra (K)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Asahiro Morishita (A)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Yao-Chun Hsu (YC)

Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

Ju Dong Yang (JD)

Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Hirokazu Takahashi (H)

Liver Center, Faculty of Medicine, Saga University Hospital, Saga University, Saga, Japan.

Ming-Hua Zheng (MH)

MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Atsushi Nakajima (A)

Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.

Cheng Han Ng (CH)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Karn Wijarnpreecha (K)

Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.

Mark D Muthiah (MD)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Amit G Singal (AG)

Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA.

Daniel Q Huang (DQ)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: daniel_huang@nus.edu.sg.

Classifications MeSH